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Abstract 
Appetite regulation by nutritional intervention is required early in life that involves the anti-aging 
gene Sirtuin 1 (Sirt 1) with Sirt 1 maintenance of other cellular anti-aging genes involved in cell 
circadian rhythm, senescence and apoptosis. Interests in anti-aging therapy with appetite regula-
tion improve an individual’s survival to metabolic disease induced by gene-environment interac-
tions by maintenance of the anti-aging genes connected to the metabolism of bacterial lipopoly-
saccharides, drugs and xenobiotics. Interventions to the aging process involve early calorie re-
striction with appetite regulation connected to appropriate genetic mechanisms that involve mi-
tochondrial biogenesis and DNA repair in neurons. In the aging process as the anti-aging genes are 
suppressed as a result of transcriptional dysregulation chronic disease accelerations and con-
nected to insulin resistance, non-alcoholic fatty liver disease (NAFLD) and neurodegenerative 
diseases such as Parkinson’s disease and Alzheimer’s disease. Interests in the gene-environment 
interaction indicate that the anti-aging gene Sirt 1that regulates food intake has been repressed 
early in the aging process in various global populations. The connections between Sirt 1 and other 
anti-aging genes such as Klotho, p66Shc (longevity protein) and Forkhead box proteins (FOXO1/ 
FOXO3a) have been associated with programmed cell death and alterations in these anti-aging 
genesregulate glucose, lipid and amyloid beta metabolism that are important to various chronic 
diseases. 
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1. Introduction 
The hypothalamus is involved with many biological functions and includes appetite and body weight control, 
feeding, emotion, memory, thermoregulation, fluid balance and insulin regulation [1]-[3]. The hypothalamic nu-
clei that are involved in food intake include the arcuate nucleus, the paraventricular nucleus, the lateral hypotha-
lamic area, the ventromedial nucleus and dorsomedial nucleus. Arcuate nucleus neurons at the bottom of the 
hypothalamus near the third ventricle have direct contact with peripheral satiety factors like leptin and insulin. 
Neurons in the hypothalamus are responsible for various connections to other brain regions and one of the im-
portant functions of the hypothalamus is control of the daily light dark cycle. The suprachiasmatic nucleus 
(SCN) that coordinate the neuronal, humoural systems and the circadian rhythms activate the arcuate nucleus 
that releases neuropeptide Y (NPY) and agouti related protein (AgRP) that control physiological functions 
(body) temperature, melatonin release, glucocorticoid secretion and behavioural functions (feeding and mem-
ory). The SCN and peripheral oscillators are altered by food availability with calorie restriction important in the 
maintenance of the SCN and the synchrony of the peripheral clocks. The neurons in the hypothalamus (appetite 
centre) are sensitive to apoptosis and become senescent early in life with relevance to global chronic diseases 
such as non-alcoholic fatty liver disease (NAFLD), obesity and diabetes. 
In neurodegenerative diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) neurons in 
specific regions of the brain become apoptotic later in life but may not involve the neurons in the appetite centre. 
Neurodegenerative diseases such as PD and AD have become the cornerstone of brain research with appetite 
dysregulation and insulin resistance now closely connected to these diseases. Early neuron transcriptional dys-
regulation that involves the SCN leads to food intake disorders and it cannot be excluded that neurons in the ap-
petite centre are defective early in life in global populations with appetite dysregulation associated with neu-
rodegenerative diseases such as PD and AD. Appetite dysregulation is connected to the anti-aging gene Sirtuin 1 
(Sirt 1) that is connected to the circadian rhythm with effects on the endocrine and metabolic systems that in-
volve diseases of the adipose tissue, heart, liver, pancreas and brain [4]-[6]. Neuron apoptosis and survival 
[7]-[10] is determined by Sirt 1 and other anti-aging genes and interventions that prevent down regulation of 
anti-aging genes may allow appetite regulation with prevention of other chronic diseases. The rise in NAFLD in 
global populations [11] [12] has required early intervention with connections to the severity of diseases such as 
obesity, diabetes and neurodegenerative diseases. Interests in the calorie restriction with stabilization of anti- 
aging genes have accelerated in recent years to delay and prevent programmed cell death linked to the various 
chronic diseases (Figure 1). Interventions such as diet and lifestyle in chronic diseases such as obesity, diabetes 
and cardiovascular disease involve abnormal post-prandial lipid metabolism [13] [14]. Diet is strongly associ-
ated with insulin and insulin like growth factor-1 (IGF-1) with cell senescence (mitochondrial apoptosis) and 
genotoxic stress linked to the global NAFLD and neurodegeneration [15]-[21]. 
Interest in genomics that leads to the identification of novel genetic pathways assists in the treatment of vari-
ous chronic diseases with the new knowledge that may delay early programmed cell death pathways in cells. 
Nutritional interventions that are controlled by the consumption of a low calorie diet indicate the maintenance of 
connections between Sirt 1 and other anti-aging genes such as Klotho, p66Shc (longevity protein) and FOXO1/ 
FOXO3a that have been connected to the cell death by effects on glucose, lipid and amyloid beta metabolism. 
These anti-aging genes in neurons are involved in transcriptional regulation with effects that are important to 
SCN control of food intake and to the survival and stability of neurons. High fat diets that induce cell senes-
cence are linked to cell transformation and are associated with liver cell dysfunction (NAFLD), adipogenesis 
disorders (obesity) and other organ diseases (Figure 1). The severity of endocrine and metabolism disorders are 
associated with poor neuron survival with early neuron transformation that leads to appetite dysregulation with 
overeating linked to metabolic disease. Major advances in the early diagnosis of diseases such as NAFLD and 
neurodegenerative disease associated with obesity and diabetes are required. Diagnostic blood assays such as 
plasma cholesterol measurements may not determine early senescence and programmed cell death [22] and ex-
tensive blood testing that is now underway in global populations may not be relevant to liver cell or neuron 
apoptosis (neurodegenerative diseases). The role of diets that control the absorption of bacterial lipopolysaccha-
rides (LPS) are critical to prevent NAFLD and neurdegeneration [23] and the repression of anti-aging genes are 
possibly linked to LPS with the acceleration of appetite dysregulation and chronic diseases. The effects of LPS 
may also interfere with IGF-1 mediated expression of anti-aging genes with IGF-1/p53 transcriptional regulation 
linked to Sirt 1 regulation of cell survival in aged and stressed cells [15]-[21]. To improve appetite dysregulation  
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Figure 1. Anti-aging strategies involve the maintenance of appetite regulation and 
insulin resistance that are connected to the anti-aging genes that are suppressed early 
in life. Appetite dysregulation accelerates abnormal post-prandial lipid metabolism 
and NAFLD in global populations and early intervention is required to prevent the 
severity of diseases such as obesity, diabetes and neurodegenerative diseases. Appetite 
maintenance improves the endocrine and metabolic system that is connected to blood 
brain barrier (BBB) disease and various organs diseases.                                  
 
and prevent overeating that is linked to gene-environment effects (stress) on metabolic disease the maintenance 
of the apelinergic pathway [24] early in life is essential. Nitric oxide (NO) is involved in appetite regulation and 
NO disturbances have been reported in various chronic diseases [25]. Diets that are high in NO override cell NO 
maintenance that is controlled by Sirt 1 relevant to endocrine, metabolic disease and thrombosis [24]-[27]. The 
effects of stress and xenobiotics (environment) are associated with cell NO disturbances that prevent the reversal 
of cell senescence (Figure 2). The nutritional diets that maintain the anti-aging genes and NO cell homeostasis 
possibly involve Sirt1/IGF-1 [29]-[36] with the effects of dietary LPS involved in the NO dyshomeostasis, neu-
ron senescence and apoptosis. 
Zinc deficiency and chronic disease has become important with zinc levels relevant to hormone bioactivity [3], 
Sirt 1 activity [28] and IGF-1 functions [37] [38]. Zinc supplementationhas become important to LPS toxicity 
with relevance to inflammation in various global populations [39] [40]. Appetite regulation has been associated 
with various neuropeptides such as brain derived neurotrophic factor (BDNF) and NPY, hormones such as insu-
lin, adiponectin, leptin and various intestinal peptides [3] [41]-[43]. The role of zinc and Sirt 1 that involved in 
the regulation of the anti-aging genes has become important since repression of these genes do not maintain the 
action of the various neuropeptides, hormones and intestinal factors involved in appetite regulation with rele-
vance to chronic diseases. Anti-aging therapy that maintains appetite regulation improves an individual’s sur-
vival against autonomous disease induced by the environment (bacterial lipopolysaccharides, drugs, xenobiotics) 
in various communities. Diets that are nutritional activate cellular anti-aging genes with the prevention of cell 
senescence and apoptosis. Appetite regulation maintains the autonomic innervation of the liver by the brain with 
the maintenance of rapid post-prandial lipid metabolism [13] [14] and the prevention of diseases of the adipose 
tissue, heart, and pancreas. 
2. Repression of Anti-Aging Genes Determine Food Intake Regulation, Insulin  
Resistance and Neurodegenerative Disease 
Overnutrition in chronic disease is involved with central nervous system dysregulation of neuropeptides with 
abnormal peripheral hormone signalling from the pancreas (insulin), adipose tissue (leptin and adiponectin) and 
gastrointestinal tract (neuropeptides) involved in chronic diseases. The increases in global chronic disease in the  
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Figure 2. The acceleration of chronic diseases involve NO disturbances 
linked to stress, consumption of unhealthy diets and xenobiotics (gene-envi- 
ronment interactions). Endocrine and metabolic diseases are linked to appetite 
dysregulation with NO disturbances that involve defective apelinergic path-
ways. Nutritional diets maintain the anti-aging genesand NO cell homeostasis 
with the importance of Sirt1/IGF-1 interactions in NO homeostasis, neuron 
senescence and apoptosis. Sirt 1 is involved with the circadian rhythm and 
platelet apoptosis with relevance to thrombosis and embolism.                           
 
past 20 years have indicated that insulin resistance and organ suicide are closely connected. The role of the mi-
tochondria in organ function is critical with increased mitochondrial apoptosis with accelerated aging. The role 
of anti-aging genes in organ disease has become of central interest to maintain mitochondria functions and the 
identification of longevity genes that determine their function is critical to the maintenance of chronic diseases. 
The association between senescence and chronic disease now indicate that the anti-aging genes have been sup-
pressed (autonomous disease) and insulin resistance, IGF-1 levels and neuropeptide disturbances are closely 
connected to mitochondria aging and cell senescence. Defective anti-aging genes are associated with glucose 
dysregulation with inhibition of insulin signalling involved with mitochondrial apoptosis. In SCN neurons 
within the brain the anti-aging genes that are involved with appetite regulation become altered by altered gene 
expression and abnormal posttranscriptional regulation closely connected to appetite dysregulation. The SCN 
synchrony between neurons is essential to maintain circadian rhythms and disturbances between neurons are as-
sociated with autonomous neuron disease linked to the anti-aging gene repression and liver dysfunction.  
The gene that is involved in the regulation of food intake is Sirtuin 1 (Sirt 1) that is linked to life span, obesity 
and cardiovascular disease with effects on NAFLD, inflammation, energy metabolism, cognition, mitochondrial 
biogenesis, neurogenesis, glucose/cholesterol metabolism and amyloidosis. Sirt 1 is a nicotinamide adenine di-
nucleotide (NAD+) dependent class III histone deacetylase (HDAC) that targets transcription factors to adapt 
gene expression to metabolic activity and is involved in the deacetylation of the nuclear receptors with its criti-
cal involvement in insulin resistance. Sirt 1 is also involved in telomerase reverse transcriptase and genomic 
DNA repair with its involvement in telomere maintenance that maintains chromosome stability and cell prolif-
eration. Sirt1 is essential for neurogenesis and calorie restriction activates Sirt1 with effects on longevity by 
modulation of phosphoinositide 3 kinase pathways and age associated cardiovascular changes. Tissue nuclear 
receptors undergo deacetylation of histone and non-histone targets by Sirt 1 that targets transcription factors 
peroxisome proliferator-activated receptor-gamma coactivator (PGC-1 alpha), p53, pregnane x receptor (PXR) 
to adapt gene expression to metabolic activity, insulin resistance and inflammation. Sirt 1 is linked to glucose 
regulation with the involvement of Forkhead box protein O1 (FOXO1) deacetylation (apoptosis) that involve 
p53 transcriptional dysregulation and peroxisome proliferator activated receptor (PPAR) gamma nuclear recep-
tor. Furthermore Sirt 1/p53 interactions may regulate adipocytokines and immune responses that may be impor-
tant to NAFLD, obesity and neurodegeneration. Interests in calorie restriction, appetite regulation and neurode-
generation that involve Sirt 1 mediated regulation of other anti-aging genes involve p53 and FOXO deacetyla-
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tion that has attracted interest in relation to autonomous disease of the brain and liver. In these tissues Sirt 1 is an 
important gene involved in maintenance of the mitochondria and deacetylation of the transcriptional factor 
FOXO3a that represses Rho-associated protein kinase-1 gene expression with activation of the non amyloido-
genic α-secretase processing of the amyloid precursor protein and reduction of amyloid beta (Aβ) generation in 
neurons. Sirt 1 is also involved with hepatic cholesterol regulation with effects on liver nuclear receptors in-
volved with cholesterol flux and metabolism. Overnutrition is associated with the repression of Sirt 1 and other 
anti-aging genes (Figure 3) such as Klotho, p66Shc (longevity protein) and FOXO1/FOXO3a that is now con-
nected to autonomous diseases of the brain and liver with SCN disturbances induced by Sirt 1 repression and 
IGF-1 dysregulation involved in programmed cell death relevant to various chronic diseases such as obesity, 
diabetes, PD and AD. 
2.1. Klotho 
The klotho (KL) gene is composed of 5 exons and encodes a type-I single pass transmembrane protein (1014- 
amino acid-long), short intracellular domain (10-amino acidlong). The extracellular domain is composed of two 
domains, termed KL1 and KL2, with weak homology. Klotho knockout mice have a short life span with in-
creased oxidative stress associated with atherosclerosis, osteoporosis, infertility, and cognitive decline. The gene 
for the mammalian KL has two transcripts encode a long type I transmembrane protein and a short secreted pro-
tein that is released from the cell membrane and found in the serum and cerebrospinal fluid (CSF) [44] [45]. Sirt 
1 and its close involvement as a histone deacetylase may be involved with Kotho gene expression and Sirt 1 
downregulation may be intimately involved in the secretion and release of the protein into the serum or CSF. 
Resveratrol is closely involved in Sirt 1 upregulation and studies indicate that Klotho gene expression and secre-
tion is upregulated by resveratrol [46]. Klotho gene has been identified as an important regulator of age related 
diseases and is involved with cell senescence by upregulation of p21 [47]. Klotho is an anti-aging gene and in 
Klotho-deficient mice Klotho has been associated with a premature aging-like syndrome. These results demon-
strate that Klotho normally regulates cellular senescence by repressing the p53/p21 pathway that is activated by 
DNA damage and causes G(1)-phase arrest in mammalian cells. Klotho has been reported as a secreted Wnt an-
tagonist and a tumor suppressor [48]. Epigenetic silencing of klotho has been shown as a major pathway with 
the involvement of histone deacetylation in the transcriptional repression of Klotho is correlated with promoter  
 
 
Figure 3. The anti-aging gene Sirt 1 is associated with transcriptional regulation and linked to insulin 
resistance, cancer and NAFLD. Sirt 1 regulation of p53, PGC1-alpha, PXR, PPAR, AMPK, FOXO1 
involve nutrient, xenobiotic metabolism with relevance to DNA repair and the immune system. Tran-
scriptional regulation of Sirt 1/p53 interactions are associated with alpha synuclein and amyloid beta 
interactions with the abnormal p53 transcriptional regulation of the anti-aging genes (Sirt 1, Klotho, 
p66Shc (longevity protein), FOXO1/FOXO3a) associated with IGF-1 and cancer.                              
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CpG hypermethylation and linked to Sirt 1 gene silencing that involve CpG island methylation. Klotho protein 
has been indicated to be a hormone that inhibits the intracellular insulin/IGF-1 signaling cascade [49] [50]. In 
other studies Klotho has been shown not inhibit IGF-1 and/or insulin signaling in various cells such as HEK293, 
L6, and HepG2 cells and indicate against the role of Klotho in insulin resistance as an important regulator of 
aging. Klotho gene expression was not associated with telomere length and the association with aging via other 
mechanisms [51]. Klotho has been associated with cognition [52] and chronic kidney disease via the fibroblast 
growth factor 23 but klotho levels have remained unchanged [53]. 
2.2. p66Shc  
The gene SHC1 is located on chromosome 1 and encodes 3 main protein isoforms: p66Shc, p52Shc and p46Shc 
and differ in molecular weight. p66Shc, a 66 kDa proto-oncogene Src collagen homologue (Shc) adaptor protein 
is a longevity protein and has many effects involved with cell receptor tyrosine kinase signal transduction, nu-
trient metabolism and increased levels of p66Shc (Ser phosphorylation) have been shown to block mitosis, in-
hibit glucose metabolism and associated with the regulation of reactive oxygen species induced cell apoptosis 
[54]-[57]. p66Shc antagonizes insulin and mTOR effects which limits glucose uptake and inhibits anabolic me-
tabolism [58] [59]. The p66shc protein plays key role in oxidative stress, stroke, metabolic disease in various 
organs and tissues in obesity and diabetes [60]-[64]. The p66Shc isoform has inhibitory effects on the Erk path-
way [65] in skeletal muscle myoblasts, actin cytoskeleton polymerization and glucose transport. p66Shc inhibits 
ERK1/2 activity and antagonize mitogenic and survival abilities of T-lymphoma Jurkat cell lines. The 
MAPK/Erk signaling cascade is activated by a wide variety of receptors involved in growth and differentiation 
including receptor tyrosine kinases (RTKs), integrins, and ion channels. Oxidized lipids and LDL have been 
shown to stimulate p66Shc expression that is associated with abnormal redox balance, endothelial dysfunction 
and cardiovascular disease [66]-[68]. p66Shc is involved with the expression of p53 and p53 isoform (p44/p53), 
oxidative stress and G2M cell cycle arrest [69]-[71]. The induction of angiotensin II regulated p66Shc is con-
trolled by stress activated p53 and indicates that post transcriptional regulation by p53 of p66Shc is essential for 
endothelium dependent vascular relaxation [72]. Sirt 1 is primarily involved in the deacetylation of p53 with 
control of p66Shc cellular senescence associated with the progression of NAFLD. Repression of p66Shc expres-
sion by Sirt 1 has been shown to be involved with liver injury and hyperglycemia induced endothelium dysfunc-
tion [73]. Palmitic acid is an inhibitor of Sirt 1 and palmitate has been shown to increase p66Shc (Ser phos-
phorylation) in pancreatic beta cells [74]. p53 is closely involved with the palmitate-induced increase in p66Shc 
expression and beta cell apoptosis. Sirt 1 that is actively involved in Aβ metabolism in neurons and Aβ has now 
been connected to the phosphorylation of p66Shc at the serine 36 residue with increased oxidative stress that 
leads to cell death [75] [76]. Antioxidants have been shown to be involved with reduced oxidative stress by in-
terfering with the phosphorylation of p66Shc. Sirt 1 has effects on brain and liver alpha-synuclein and Aβ me-
tabolism closely linked metabolic disease [77] [78] with effects of p53 transcriptional regulation by intracellular 
alpha-synuclein and Aβ metabolism in the liver and brain linked to the regulation of anti-aging genes and cellu-
lar apoptosis [78] [79].  
2.3. FOXO3a 
FOXOs belong to the O subclass of the Forkhead family of transcription factors which are characterized by a 
Forkhead DNA binding domain. There are three main proteins (FOXO1, FOXO3a and FOXO4) from which 
FOXO3a protein is considered to be a regulator of cancer and aging [80]-[83]. FOXO1 proteins are involved 
with adipocyte lipid metabolism and ROS-dependent cascades. FOXO3a is found in the nucleus but is redistrib-
uted to the cytosol by the actions of ROS and activation of this pathway (insulin/insulin-like growth factor-1 
(IGF-1)/phosphatidylinositol-3 kinase (PI3K)/Akt/FOXO3a) is associated with senescence [84]. p66Shc partici-
pates in Akt signaling pathway and is involved with inactivated FOXO3a and ROS effects that involve activated 
p38 and JNK and inactivated by Akt kinase in cells. Sirt 1 has been shown to deacetylate FOXO3 and FOXO4 
with the regulation of FOXO-induced apoptosis and cell-cycle arrest not connected to p53 deacetylation. Sirt 1 
has been shown to interact with FOXO3a and induce cell apoptosis [85] [86]. Nuclear Sirt 1 actively involved in 
Aβ metabolism and possibly regulates FOXO associated senescent effects with control of cell survival. Klotho 
has been shown to activate FOXO and to inhibit the insulin/IGF-1/PI3K/Akt signaling cascade. The connections 
between Sirt 1 and Kotho for cell senescence possibly are connected via FOXO1/FOXO3a mediated glucose 
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homeostasis and ROS pathways. Bacterial lipopolysaccharides (LPS) are involved in the repression of Sirt 1 
with the actions on other anti-aging genes. Zinc is the activator of Sirt 1 function with LPS closely connected to 
zinc deficiency with zinc supplementation essential to reduce LPS toxicity [38] [39]. Sirt 1’s effects on cellular 
cholesterol homeostasis is by its deacetylase activity and ubiquitination of liver X receptor (LXR) proteins with 
the regulation of ATP-binding cassette transporter (ABCA1) and sterol regulatory element-binding protein 
1cinvolved in cell cholesterol homeostasis [78] [79]. LPS interferes with Sirt 1 and ABCA1 interactions by in-
hibition of cholesterol flux via LXR-ABCA1 pathways [78] [79]. Sirt 1 regulation of PGC1 alpha is well under-
stood with PGC1 alpha involved in the inactivation of prostaglandain E2 (PGE2) with fat accumulation [11]. 
LPS is involved in the biosynthesis of PGE2 with LPS effects in the liver and other cells that override Sirt 1and 
PGC1 alpha effects in these cells [87] [88]. The major effects of Sirt 1 as a deacetylase is regulation of the tran-
scription factor p53 involved in the regulation of cell glucose and cholesterol metabolism [79]. LPS is involved 
in the post-transcriptional regulation of p53 with interference of Sirt 1/p53 cell regulation pathways involved in 
cell maintenance [79]. LPS induces mitochondrial apoptosis with toxic effects on the SCN neurons involved 
with appetite regulation that involve Sirt 1 dysregulation linked to anti-aging genes [78] [79]. IGF-1 levels and 
its connections to Sirt 1 and the anti-aging genes possibly involve corruption by LPS with LPS effects that in-
volve dysregulation ofcircadian regulation of IGF-1 with IGF-1 effects on nuclear genes (cancer) and mitochon-
dria within cells [17]-[19] [89]-[91]. Sirt 1 and its regulation of the SCN and appetite centre are inhibited by 
LPS via interference of the Sirt 1/p53 pathways that involve the other anti-aging genes. 
3. Dysregulation of Neuropeptides and Endocrine Hormones by LPS Determine  
Appetite and Metabolism Disorders 
The SCN in the brain is closely involved with appetite regulation and LPS induced posttranscriptional regulation 
in neurons is now closely connected to appetite dysregulation. The SCN synchrony between neurons is essential 
to maintain circadian rhythms and disturbances between neurons are associated with autonomous neuron disease 
linked to appetite dysregulation. LPS has a number of effects on various cells and tissues in the periphery and in 
the brain. LPS induces dyslipidemia and NAFLD with effects on apolipoproteins (apo E, apo AI), acute phase 
proteins, cytokines, albumin, alpha synuclein and amyloid beta [77] [78]. Its preference for binding to choles-
terol and sphingomyelin sites on cell membranes indicates its role in the electrostatic interaction of amyloid beta 
[23] [77]. LPS has marked effects on receptors and on the astrocyte-neuron interaction with the induction of 
neuroinflammation [77]. LPS effects on the sleep/wake cycle determines food intake regulation and LPS effects 
on appetite regulation involves Sirt 1 repression and alpha synuclein/IGF-1 metabolism [78] [92]-[95]. Neurons 
in the hypothalamus are responsible to various brain regions and LPS induction of nuclear, mitochondria and 
cell membrane interactions induces autonomous cell behaviour with appetite dysregulation linked to reorganiza-
tion cell signalling and astrocyte-neuron synchrony in the brain. Autonomous disease interferes with the effects 
of neuropeptides and hormones that are no longer effective and are now connected to nuclear receptors dysfunc-
tion associated with the anti-aging genes. Appetite regulation has been associated with various neuropeptides 
such as BDNF and NPY, hormones such as insulin, adiponectin, leptin and various intestinal peptides [96].  
The interests in LPS in the induction of autonomous neuron disease involve inflammation with the connec-
tions to poor neuropeptide/receptor and peripheral hormones interactions that promote appetite dysregulation in 
the brain. NO has been clearly linked to food intake regulation and autonomous neuron disease induced by LPS 
is relevant overeating and metabolic disease in global populations (Figure 2). The effects of LPS induce mito-
chondrial apoptosis with NO dyshomeostasis [97]-[100] and corrupt appetite regulation by interference with 
neuropeptides and peripheral hormones that are also involved in the maintenance of mitochondrial stability. The 
effects of LPS on nuclear Sirt 1 repression in neurons disturb Sirt 1 regulation of cell NO metabolism with Sirt 1 
linked to mitochondrial biogenesis [79]. The effects of LPS in the brain and the liver corrupt the autonomic in-
nervation of the liver by the brain [101] with the liver clocks under autonomous regulation with sensitivity to 
disturbed post-prandial metabolism, liver steatosis and NAFLD. Interest in metabolic disorders indicate that the 
communication between the gastrointestinal tract neuropeptides involve the hypothalamus and brain stem [3].  
These regions of the brain integrate peripheral signals such as various factors released from the gut and adi-
pose tissue that have effects on neuronal activity of the hypothalamus and brain stem that control appetite regu-
lation. In response to food intake various gut and adipose tissue hormones have effects on the hypothalamus that 
release various neuropeptides that effect appetite, food intake and energy balance. Cholecystokinin (CCK) is an 
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intestinal hormone and after a meal CCK levels rise to inhibit food intake. Other peptides involved in appetite 
regulation include glucagon like peptide (GLP-1) that increases in the blood plasma released from the L cells of 
the gastrointestinal tract. Pancreatic islet beta cells release insulin and another peptide referred to as amylin is 
released with relevance to reduced food intake. Other proglucagon cleavage peptides including oxyntomodulin 
(OXM) and peptide YY (PYY) are secreted with GLP-1 in response to high calorie foods. Pancreatic polypep-
tide (PP) is secreted from the pancreatic islets and is similar in structure to PYY with reduction in food intake 
after administration to rodents and humans. PP has effects on gastric ghrelin and gene expression of hypotha-
lamic peptides such as NPY and AGRP that control food intake. Ghrelin is 28 amino acid peptide hormone and 
has been characterized as an appetite stimulating hormone with effects on appetite control related to hypotha-
lamic NPY/AgRP neurones which express the ghrelin receptors [3].  
Future therapies that involve control of body size and adiposity will involve assessment of diets that reduce 
LPS absorption [23] with relevance to LPS effects on the hypothalamus and on the poor regulation of various 
intestinal and brain neuropeptides that influence appetite regulation. Influence on appetite regulation and feeding 
are also related to leptin, melanortin, adiponectin, melanin concentrating hormone (MCH), orexins and endo-
cannabinoids that communicate with peripheral signals such as nutrients (glucose, amino acids, fatty acids) and 
gastrointestinal peptide hormones such as CCK and ghrelin. Thyroid hormones may act directly on the hypotha-
lamic appetite circuits and signalling factors such as thyroid stimulating hormone, triiodothyronine (T3) and 
thyroxine (T4) have recently shown to directly influence food intake. Hypothalamic control of appetite regula-
tion and energy expenditure not only involves the hypothalamus but also the hypothalamic pituitary axis (HPT). 
Recent evidence indicates that the HPT axis can control food intake and effects on appetite and body weight is 
mediated by thyroid hormones and LPS has become important to appetite regulation [102] [103]. Interests in the 
neuroendocrine system, energy metabolism and peripheral cholesterol metabolism have increased with the 
strong genetic identification andinvolvement NPY in plasma cholesterol regulation.  
The CNS and its control of lipidmetabolism has identified hypothalamic NPY with evidence that NPY has 
effects onY1 receptors to promote hepatic lipoprotein secretion to promote VLDL secretionvia the sympathetic 
nervous system [104] [105] and on Y2 receptors to promote feeding. Sirt 1 regulation of BDNF [106]-[108] has 
been shown (Figure 4) and associated with altered NPY levels in the brain [109] [110] and several studies have 
indicated its involvement in neuronal plasticity, behaviour, appetite control andbody weight regulation. BDNF is 
involved in the regulation of food intake and the levels of BDNF controlled by high fat diets. In mature neurons 
the BDNF peptide is involved with the regulation of synaptic plasticity and neuro transmission in the peripheral 
 
 
Figure 4. Bacterial LPS suppresses Sirt 1 expression with effects on 
neuropeptides such as brain derived neurotrophic factor, neuropeptide Y 
and IGF-1 that are involved in the appetite regulation (food intake) in 
the brain and in the periphery LPS interrupts hepatic glucose, lipopro-
tein and cholesterol metabolism. LPS is involved in cell zinc homeosta-
sis with the importance of zinc relevant to the maintenance of Sirt 1 activ-
ity and the function of hormones such as insulin and the adipokines (ad- 
iponectin, leptin) involved in appetite regulation in the hypothalamus.                 
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and central nervous system. BDNF is involved in regulation of CB1 receptor expression and the proliferation, 
survival and maintenance of neurons. In individuals with the metabolic syndrome Sirt 1 downregulation is pos-
sibly related to BDNF levels [111], IGF-1 levels and abnormal NPY regulation involved with appetite dysregu-
lation and neurodegeneration. 
Zinc deficiency has marked effects on brain zinc homeostasis and is associated with alterations in behaviour, 
learning and mental function. Under stress, anxiety and depression disorders zinc levels alter with marked ef-
fects on health and well being of the individuals. Stress has been linked to body weight regulation and evidence 
suggests zinc’s involvement in the molecular mechanisms of brain function and appetite control. Zinc is in-
volved with regulation of leptin, insulin and adiponectin levels, adipose tissue cytokines (interleukin 2 and tu-
mour necrosis factor) with long term effects on appetite regulation in the brain.  
In zinc deficiency NPY levels in the hypothalamus are increased and release of NPY from the paraventricular 
nucleus is impaired with effects on regulation of food intake [112] [113]. In zinc deficiency NPY is unable to 
bind to its receptors to intiate an orexigenic response. Zinc is involved in the expression of brain BDNF and 
NPY synthesis and its effects on insulin, leptin and adiponectin [3] in the peripheryindicates its role in the close 
relationship between appetite control and cholesterolhomeostasis. Zinc is an activator of Sirt 1 and plays a criti-
cal role in the biology of p53 that is involved in the binding of p53 to DNA [114]. Interests in alpha-synuclein 
and food intake have increased [92] [93] and its relevance to p53 transcriptional regulation has been shown with 
LPS involvement [78] [79]. LPS regulation of apo E (23) has become important with relevance to apo E sup-
pression of food intake [115]-[117] and LPS effects on leptin synthesis may determine appetite regulation [118] 
[119]. Leptin is a 16 kda protein identified in 1994 (14) is synthesized by fat cells and acts as a satiety factor at 
the hypothalamus mediated through the leptin receptor. The amount of leptin released is proportional to the size 
of adipose tissue and regulates food intake. LPS has effects on adipose tissue with release of free fatty acids as-
sociated with insulin resistance [120]. Dietary fat that promotes LPS absorption may determine apo E and leptin 
synthesis in the hypothalamus with relevance to chronic automomic disease that involveszinc deficiency, appe-
tite dysregulation and insulin resistance.  
4. Anti-Aging Therapy Involves Reversal of Appetite Disorders in Autonomous  
Chronic Diseases 
In the aging process appetite dysregulation (overeating) is connected to the suppression of the anti-aging genes 
as a result of transcriptional dysregulation. Interests in the gene-environment interaction [121] [122] indicate 
that the anti-aging gene Sirt 1 that regulates food intake is repressed early in the aging process in various global 
populations. Repression of Sirt 1 and other anti-aging genes such as Klotho, p66Shc (longevity protein) and 
FOXO1/FOXO3a lead to abnormal regulation of glucose, lipid and amyloid beta metabolism that are associated 
with programmed cell death in the liver and brain. Dietary effects on stress sensitive anti-aging genes (repres-
sion) may be associated with Sirt 1 downregulation with appetite dysregulation and accelerated disease progres-
sion. Anti-aging therapy that maintains appetite regulation improves an individual’s survival against autono-
mous disease induced by the environment in various communities. Bacterial lipopolysaccharides, drugs, and 
xenobiotics consumed early in life induce autonomous chronic disease and corrupt the Sirt 1 circadian clock 
gene with dysregulation of other cellular anti-aging genes now associated with cell senescence and apoptosis. 
Furthermore the lack of ingestion of nutritional doses of phosphatidylinositol (appetite regulation) leads to liver 
steatosis and acceleration to NAFLD. In the current global NAFLD in developing countries [122] [123] the in-
duction of autonomous liver disease by consumption of high calorie diets that contain LPS, xenobiotics and 
drugs is now relevant to neurodegenerative diseases such as PD and AD. LPS and xenobiotics inactivate liver 
cells (autonomous liver disease) with relevance to the defective peripheral sink abeta clearance pathway that is 
now relevant to many chronic diseases [11] [124] that before may have been previously only associated with 
neurodegeneration [77]. The role of anti-aging genes in various communities in the developing world may be 
altered early in life with the acceleration of various diseases [11]. In the developed world the xenobiotic free diet 
and appropriate zinc consumption may activate hepatic nuclear receptors and with the metabolic syndrome the 
malfunction of various organ diseases may not be associated with the insulin resistance epidemic [125]. To 
maintain the cell anti-aging gene mechanisms and prevent early programmed cell death diets that are very low 
carbohydrate diets need to be ingested to avoid the intestinal absorption of LPS into the blood that is found in 
various foods [14]. The low calorie diet will maintain the nuclear Sirt 1 activity with relevance to p66Shc 
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mechanisms that are sensitive to the ingestion of high palmitic acid and leads to cell cycle dysregulation with 
cell apoptosis [74] [126]. Short chain fatty acids (SCFA) have become important to appetite regulation with the 
consumption ofacetate, propionic acid and butyric acid at therapeutic doses applicable to central appetite regula-
tion [127] [128]. Butyric acid has been associated with the inhibition of zinc associated HDACs and administra-
tion of butyric acid doses in man for the reduction of alpha-synuclein and Aβ oligomers [78] [129] may inhibit 
the zinc sensitive HDACs such as Sirt 1 involved in cell NO homeostasis [129]. LPS sensitive butyric acid 
events have been associated with T cell apoptosis and cancer (Figure 5) with butyric acid derivatives important 
to cancer treatment [130]. The use of SCFA in nutritional diets has attracted interest to appetite regulation but 
the doses of the SCFA have become of concern for use in man and administration of butyric acid may need to be 
assessed with relevance to plasma LPS levels that may corrupt the neuroprotective effects of a ketogenic diet 
[131]. 
Sirt 1 activators (nutrients) and inhibitors (drugs, alcohol) have been previously described [11] and their con-
sumption in various countries will determine nuclear receptor function and insulin resistance and determine the 
origin of autonomous chronic disease associated with early liver dysfunction linked to organ disease progression. 
Diets that are high in NO override the Sirt 1/ p66Shc regulation of cell NO (Figure 5) and mitochondrial apop-
tosis linked to cell autonomous disease are possibly associated with the acceleration of obesity, diabetes and 
neurodegeneration [25] [132]. The major interest in cell anti-aging genes is relevant to specific dietary intake 
that allows Sirt 1 cell function to belinked to therapeutic neuropeptide and endocrine responses that lead to the 
maintenance of anti-aging cellprocesses with the prevention of NO related apoptosis [133]-[135]. Interactions 
between cells in various tissues such as the liver and brain have become important with the brain involved in the 
autonomic regulation of liver function. The liver clock [136] may override the automonic regulation of brain 
control by autonomous behaviour between cells that may be induced by LPS, mycotoxins or xenobiotics [137] 
with dysregulation of neuropeptides and endocrine hormones. Mycotoxins, LPS and xenobiotics that may be 
transported to the brain may induce cell desynchrony with appetite dysregulation and overeating related to dys-
regulation of neuropeptides and endocrine hormones important to insulin and the IGF-1 signaling cascade. The 
synergism between LPS, mycotoxin and xenobiotics in diets may override the function of the anti-aging genes 
with the liver autonomous to brain regulation with the development of obesity and diabetes. The intestine and its 
release of lipid particles such as chylomicrons after a meal [14] has become important to human disease with in-
testinal release of lipid particles that contain LPS, xenobiotics and mycotoxins. The fat content of diet that re-
leases the number and size of the intestinal particles has become important [138] to the function of the anti-ag- 
ing genes in liver cells and food restriction (chylomicron release) that allows maintenance of anti-aging gene 
function is required. Under fasting conditions or timed meal conditions the release from the intestine of chy-
lomicrons with LPS, xenobiotic or mycotoxin to the liver may allow rapid hepatic metabolism and elimination 
 
 
Figure 5. The short chain fatty acid butyric acid has been shown to be involved in the inhibi-
tion of Sirt 1 activity with effects of butyric acid and LPS on T cell apoptosis and cancer. Bu-
tyric acid regulation of brain appetite signals involves other short chain fatty acids such as 
acetate and propionic that are important to central appetite regulation. Butyric acid inhibits Sirt 
1 with effects on the metabolism of alpha synuclein and amyloid beta metabolism in cells. 
Administration of dietary phenyl butyric acid reducesalpha synuclein and amyloid beta oli-
gomers in the brain in mice.                                                                 
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of various drugs into the bile [122] [137]. Tests for postprandial lipid metabolism in obesity indicate that in the 
fed and the fasting conditions dietary chylomicron remnant metabolism is defective with liver programmed cell 
death [14]. The various blood tests [22] and tests for postprandial lipid metabolism [14] may not allow early di-
agnosis of autonomous liver disease independent of appetite regulation that may be the primary disease associ-
ated with the current global obesity linked diabetes epidemic relevant to neurodegeneration [3] [22] [139]. The 
addition of zinc to the diet may not reverse the cell autonomy and may require the addition of various nutrients 
and the removal of various Sirt 1 inhibitors required for anti-aging cell processes. In the developing world, ab-
normal blood lipids (cholesterol, triglyceride) and liver enzymesmay not interpret the effects of LPS and my-
cotoxin on anti-aging genes in the liver and brain that are defective and the effects of the anti-aging therapy such 
as consumption of a very low carbohydrate or a low fat diet [11] are possibly able to reverse the autonomous 
cell behaviour (nuclear-mitochondria interactions) that is linked to the nuclear senescence with mitochondrial 
apoptosis [79]. The use of diet as therapy for reversal of the aging process may stabilize the apelinergic system 
[25] that is defective in individuals with insulin resistance and important to the optimal function of the brain and 
peripheral organs. The anti-aging genes in people at risk for various diseases in global populations may be de-
fective early in life and not connected to DNA methylation profile associated with aging and longevity [140].  
5. Discussion 
In Western countries and the developing world the metabolic syndrome and NAFLD and neurodegenerative 
disease has reached approximate 30% of the global population. Accelerated age related disease associated with 
cell senescence interfere the anti-aging genes that are involved with cell growth and healthy aging. Dietary in-
terventions with calorie restriction early in life prevent the tissue accumulation of LPS, mycotoxin, xenobiotics 
and drugs by maintenance of post-prandial lipid metabolism associated with delivery of various foreign com-
pounds to the liver relevant to facilitate many tissue cell to cell communications with the prevention of autono-
mous organ diseases. Anti-aging strategies that involve nutritional diets allow neuropeptides and endocrine 
hormones to maintain cell and mitochondrial functions to facilitate nutrient metabolism in the liver and brain. 
Prevention of insulin resistance has become the major prevention program in global populations with improve-
ment in zinc intake and maintenance of nitric oxide homeostasis in cells central to prevent early alterations in 
multiple anti-aging genes, neuropeptides and endocrine hormones that are associated with appetite regulation, 
insulin resistance and cell apoptosis. 
6. Conclusion 
The regulation of food intake and calorie restriction is important to appetite regulation with relevance to the 
progression of chronic disease and neurodegeneration. Appetite dysregulation involves neurons associated with 
the suppression of the anti-aging gene Sirt 1 and other anti-aging genes such as Klotho, p66Shc and FOXO1/ 
FOXO3a that are connected to the programmed cell death (mitochondrial apoptosis) and dysregulation of glu-
cose, lipid and amyloid beta metabolism. Nutritional intervention early in life with the consumption of very low 
carbohydrate diets has been recommended that allows maintenance of the autonomic innervation of the liver by 
the brain. In the aging process unhealthy diets disconnect the liver from the brain with the ingestion of LPS, 
myoctoxin and xenobiotics that induce autonomous liver disease, metabolic disease and neurodegeneration. The 
brain and liver dysregulation are connected to various chronic diseases associated with abnormal post-prandial 
lipid metabolism, cardiovascular disease, obesity and diabetes. The anti-aging therapy involves low calorie diets 
that do not contain LPS, mycotoxin or xenobiotics and these diets maintain brain and liver Sirt 1 activity with 
appetite regulation closely linked to zinc and nitric oxide homeostasis connected to the autonomic control of the 
liver by the brain. 
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